Drugs / ASTX295
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03975387 | Jul 2019 → Sep 2023 | cancer | Taiho Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASTX295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03975387 ↗ |
| Route | Oral | “ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.” NCT03975387 ↗ |